Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.

Carolyn S P LamLars KøberKoichiro KuwaharaLars H LundPatrick B MarkLinda G MellbinMorten SchouPatricia Ely PizzatoAnders GabrielsenSamvel B GasparyanAlessandro GhirettiJudith Hartleib-GeschwindnerGreggory J HouslerPaolo FantiMaria Leonsson-ZachrissonJohn J V McMurrayScott D Solomonnull null

Published in: European journal of heart failure (2024)

While the smaller than planned sample size limits interpretation, we did not see significant reduction in UACR in patients treated with balcinrenone plus dapagliflozin compared with dapagliflozin plus placebo.

Keyphrases

chronic kidney disease
phase iii
end stage renal disease
clinical trial
study protocol
randomized controlled trial
double blind
peritoneal dialysis